glp 1 and kidney disease GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Kidney Outcomes With Glucagon-Like Peptide-1
Description
This removes the need for in-person visits and makes it easier to stay consistent with treatment
In agreement with Dong et al
Your PlexusDx clinical team can assess whether microdosing aligns with your baseline health status and weight loss goals, adjusting the protocol as your tolerance improves
21 Pharmacists should also counsel patients on the importance of maintaining adequate hydration, especially in the presence of vomiting or diarrhea, to prevent dehydration and reduce the risk of acute kidney injury
[DOI] [PMC free article] [PubMed] [Google Scholar] 72.Gaulton A., Hersey A., Nowotka M., Bento A.P., Chambers J., Mendez D., Mutowo P., Atkinson F., Bellis L.J., Cibrin-Uhalte E., et al
The currently available incretin-based therapies are listed in Table 1 , and their physiologic effects are summarized in Figure 1
